Bolus administration of saruplase in Europe (BASE), a pilot study in patients with acute myocardial infarction

Journal of Thrombosis and Thrombolysis

Volumn 6, Issue 2, 1998, Pages 147-153

  Bar F W ^a   Meyer, J ^b   Boland, J ^c   Betriu, A ^d   Artmeyer, B ^e   Charbonnier, B ^f   Michels, H R ^g   Tebbe, U ^h   Spiecker, M ^b   Vermeer, F ^a   Von Fisenne, M J M ⁱ   Hopkins, G R ⁱ   Barth, H ⁱ  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^c Centre Hospitalier Regional de La Citadelle   (Belgium)

^d HOSPITAL CLÍNIC   (Spain)

^e Marien Hospital   (Germany)

^f UNIVERSITY HOSPITAL OF TOURS   (France)

^g CATHARINA HOSPITAL   (Netherlands)

^h KLINIKUM LIPPE DETMOLD   (Germany)

ⁱ GRÜNENTHAL GMBH   (Germany)

Author keywords

Acute myocardial infarction; Patency; Thrombolytic therapy

Indexed keywords

SARUPLASE;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; BOLUS INJECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INFUSION; DRUG SAFETY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

EID: 7844237879     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008809907268     Document Type: Article

References (17)

1. PRIMI Trial Study Group. Randomized double-blind trial of recombinant pro-urokinase against streptokinase in acute myocardial infarction. Lancet 1989;1:863-868.
2. Bär FW, Meyer J. Vermeer F, et al. Early patency and reocclusion: Comparison of saruplase and alteplase in acute myocardial infarction. From the SESAM study. Am J Cardiol 1997;79:727-732.
3. Michels R, Hoffmann H, Windler J, Barth H, Hopkins G. A double-blind multicentre comparison of the efficacy and safety of saruplase in the treatment of acute myocardial infarction. Report of the SUTAMI study group. Thrombos Thrombolys 1995;2:117-124.
4. Tebbe U, Windeler J, Boesl I, Massberg I, Barth H on behalf of the LIMITS Study Group. Thrombolysis with recombinant unglycosylated single chain urokinase-type plasminogen activator (saruplase) in acute myocardial infarction: Influence of heparin on early patency rate (LIMITS study). J Am Coll Cardiol 1995;26:365-373.
5. Tebbe U, Michels R, Adgey J. et al. Thrombolysis with saruplase is at least as effective in AMI as streptokinase: COMPASS double-blind study in 3089 patients. J Am Coll Cardiol 1996;166A:752-751.
6. Vermeer F, Bär FW, Windeler J, Schenkel W. Saruplase, a new fibrin specific thrombolytic agent. Final results of the PASS study (1698 patients) (abst). Circulation 1993;88:292.
7. Relik-van Wely L, Visser RF, van der Pol J, et al. Angiographically assessed coronary arterial patency and reocclusion in patients with acute myocardial infarction treated with anistreplase: Results of the Anistreplase Reocclusion Multicentre Study (ARMS). Am J Cardiol 1991;68:296-300.
8. Bonnier HJRM, Visser RF, Klomps HC, et al. Comparison of intravenous anisoylated plasminogen streptokinase activator complex and intracoronary streptokinase in acute myocardial infarction. Am J Cardiol 1988;62:25-30.
9. Mathey DG, Schofer J, Sheehan FH, Becher H, Tilsner V, Dodge HT. Intravenous urokinase in acute myocardial infarction. Am J Cardiol 1985;55:878-882.
10. Rossi P, Bolognese L. Comparison of intravenous urokinase plus heparin versus heparin alone in acute myocardial infarction. Am J Cardiol 1991;68:585-592.
11. Purvis JA, McNeil AJ, Siddiqui RA, et al. Efficacy of 100 mg of double-bolus alteplase in achieving complete perfusion in the treatment of acute myocardial infarction. J Am Coll Cardiol 1994;23:6-10.
12. Gemmill JD, Hogg KJ, MacIntyre PD, Booth N, Rea AP, Dunn FG, Hillis WS. A pilot study of the efficacy and safety of bolus administration of alteplase in acute myocardial in-farction. Br Heart J 1991;66:134-138.
13. Lincoff AM, Topol EJ. Illusion of reperfusion. Does anyone achieve optimal reperfusion during acute myocardial infarction? Circulation 1993;87:1792-1805.
14. Karagounis LA, Sorensen SG, Menlove RL, Moreno F, Anderson JL. Does thrombolysis in myocardial infarction (TIMI) perfusion grade 2 represent a mostly patent artery or a mostly occluded artery? Enzymatic and electrocardio-graphic evidence from the TEAM 2 study. J Am Coll Cardiol 1992;19:1-10.
15. Anderson JL, Karagounis LA, Becker LC, Sorensen SG, Menlove RL. TIMI perfusion grade 3 but not grade 2 results in improved outcome after thrombolysis for myocardial infarction. Ventriculographic, enzymatic and electrocardiographic evidence from the TEAM 3 study. Circulation 1993;87:1829-1839.
16. Vogt A, von Essen R, Tebbe U, Feuerer W, Appel KF, Nauhaus KL. Impact of early perfusion status of the infarct-related artery after thrombolysis for acute myocardial infarction: Retrospective analysis of four German multicentre studies. J Am Coll Cardiol 1993;21:1391-1395.
17. Ohman EM, Califf RM, Topol EJ, et al. Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. Circulation 1990;82:781-791.